Mumbai, 2nd August 2024: Supriya Lifescience Ltd., a global leader in the manufacturing of Active Pharmaceutical Ingredients (APIs), is embarking on an exciting new chapter with a major leadership reshuffle. The company is delighted to announce the appointment of the Wagh family’s next generation to key leadership positions. Dr. Saloni Wagh takes over as Managing Director, offering a fresh and innovative viewpoint. Ms. Shivani Satish Wagh takes on the role of Joint Managing Director, ready to drive strategic growth. Meanwhile, Dr. Satish Waman Wagh takes on the role of Whole-Time Director and Executive Chairman, combining considerable experience with imaginative leadership. This strategic shift demonstrates Supriya Life science’s dedication to moving forward with new enthusiasm and quality.
Dr. Saloni Wagh holds a master’s degree in science from the University of Mumbai and a Ph.D. in Chemistry from the Faculty of Science, Pacific University, Udaipur, India. With over 10 years of experience in business operations and marketing, Dr. Saloni has played an integral role in Supriya Lifescience’s success and growth, particularly in terms of revenue. Her dynamic leadership and strategic vision have been pivotal in propelling Supriya Lifescience to new heights.
Reflecting on her new role, Dr. Saloni Wagh stated, “Taking on the role of Managing Director is both a privilege and a significant responsibility. My vision is to leverage our scientific expertise and operational excellence to drive innovation and create value for our stakeholders. In a rapidly evolving pharmaceutical landscape, we must remain agile and forward-thinking, ensuring our solutions continue to meet global healthcare needs. ”
Ms. Shivani Wagh joined Supriya Lifescience Ltd. in 2014, bringing with her an impressive educational background and a lot of experience. Shivani specializes in marketing and global commerce, having earned a Bachelor of Management Studies from Mumbai University and dual master’s degrees in commerce and international business management from the University of Manchester, UK. Her strategic thoughts and thorough awareness of the pharmaceutical landscape have been critical in improving organizational success.
Ms. Shivani Wagh commented on her appointment, saying, “As Joint Managing Director, I am eager to advance our commitment to sustainability and innovation. By fostering a culture of collaboration and continuous improvement, we aim to enhance our product offerings and expand our global reach. Our focus will be on developing strategic partnerships and exploring new markets to drive our long-term growth ambitions.”
Dr. Satish Wagh, Founder of Supriya Lifescience Ltd., has been appointed as the Executive Chairman. His vast experience and visionary leadership have been instrumental in establishing Supriya Lifescience as a prominent name in the pharmaceutical industry. As Executive Chairman, Dr. Satish Wagh will continue to provide strategic direction and mentorship to the leadership team.
Dr. Satish Wagh, said, “Reflecting on our journey, I am filled with pride in the achievements of Supriya Lifescience and the strong foundation we have built. As I transition to Executive Chairman, my focus will be on empowering our leaders to take bold steps towards a sustainable future. I have immense confidence in Saloni and Shivani’s ability to lead us into our next era of growth, maintaining our commitment to excellence and innovation.”
The leadership changes are effective immediately i.e. from 1st August 2024 and mark a significant step forward in Supriya Lifescience’s journey towards sustained growth and innovation. The company remains committed to delivering high-quality pharmaceutical products and expanding its presence in key markets worldwide.
About Supriya Lifescience Ltd.:
Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company’s primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
